Cargando…

Malignant ascites in patients with terminal cancer is effectively treated with permanent peritoneal catheter

BACKGROUND: Malignant ascites is a pathological condition caused by intra- or extra-abdominal disseminated cancer. The object of treatment is palliation. In search of an effective and minimally invasive palliative treatment of malignant ascites placement of a permanent intra peritoneal catheter has...

Descripción completa

Detalles Bibliográficos
Autores principales: Meier, Michelle, Mortensen, Frank V., Madsen, Hans Henrik Torp
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4548747/
https://www.ncbi.nlm.nih.gov/pubmed/26346641
http://dx.doi.org/10.1177/2058460115579934
_version_ 1782387227283685376
author Meier, Michelle
Mortensen, Frank V.
Madsen, Hans Henrik Torp
author_facet Meier, Michelle
Mortensen, Frank V.
Madsen, Hans Henrik Torp
author_sort Meier, Michelle
collection PubMed
description BACKGROUND: Malignant ascites is a pathological condition caused by intra- or extra-abdominal disseminated cancer. The object of treatment is palliation. In search of an effective and minimally invasive palliative treatment of malignant ascites placement of a permanent intra peritoneal catheter has been suggested. PURPOSE: To evaluate our experiences with treatment of malignant ascites by implantation of a permanent PleurX catheter. MATERIAL AND METHODS: A retrospective study was conducted, comprising 20 consecutive patients with terminal cancer, who had a permanent PleurX catheter implanted because of malignant ascites in the period from February to November 2014. Using the patients’ medical records, we retrieved data on patients and procedures. RESULTS: The technical success rate was 100%. Catheter patency was 95.2%, one catheter was removed due to dislocation. Ten patients (50.0%) experienced minor adverse events. No procedural difficulties were reported and there was no need for additional treatment of malignant ascites after catheter implantation. Median residual survival after catheter implantation was 27 days. CONCLUSION: Implantation of a permanent PleurX catheter is a minimally invasive and effective procedure with only minor adverse events and a high rate of catheter patency in patients with malignant ascites caused by terminal cancer disease.
format Online
Article
Text
id pubmed-4548747
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-45487472015-09-04 Malignant ascites in patients with terminal cancer is effectively treated with permanent peritoneal catheter Meier, Michelle Mortensen, Frank V. Madsen, Hans Henrik Torp Acta Radiol Open Research BACKGROUND: Malignant ascites is a pathological condition caused by intra- or extra-abdominal disseminated cancer. The object of treatment is palliation. In search of an effective and minimally invasive palliative treatment of malignant ascites placement of a permanent intra peritoneal catheter has been suggested. PURPOSE: To evaluate our experiences with treatment of malignant ascites by implantation of a permanent PleurX catheter. MATERIAL AND METHODS: A retrospective study was conducted, comprising 20 consecutive patients with terminal cancer, who had a permanent PleurX catheter implanted because of malignant ascites in the period from February to November 2014. Using the patients’ medical records, we retrieved data on patients and procedures. RESULTS: The technical success rate was 100%. Catheter patency was 95.2%, one catheter was removed due to dislocation. Ten patients (50.0%) experienced minor adverse events. No procedural difficulties were reported and there was no need for additional treatment of malignant ascites after catheter implantation. Median residual survival after catheter implantation was 27 days. CONCLUSION: Implantation of a permanent PleurX catheter is a minimally invasive and effective procedure with only minor adverse events and a high rate of catheter patency in patients with malignant ascites caused by terminal cancer disease. SAGE Publications 2015-07-03 /pmc/articles/PMC4548747/ /pubmed/26346641 http://dx.doi.org/10.1177/2058460115579934 Text en © The Foundation Acta Radiologica 2015 http://creativecommons.org/licenses/by-nc/3.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page(http://www.uk.sagepub.com/aboutus/openaccess.htm).
spellingShingle Research
Meier, Michelle
Mortensen, Frank V.
Madsen, Hans Henrik Torp
Malignant ascites in patients with terminal cancer is effectively treated with permanent peritoneal catheter
title Malignant ascites in patients with terminal cancer is effectively treated with permanent peritoneal catheter
title_full Malignant ascites in patients with terminal cancer is effectively treated with permanent peritoneal catheter
title_fullStr Malignant ascites in patients with terminal cancer is effectively treated with permanent peritoneal catheter
title_full_unstemmed Malignant ascites in patients with terminal cancer is effectively treated with permanent peritoneal catheter
title_short Malignant ascites in patients with terminal cancer is effectively treated with permanent peritoneal catheter
title_sort malignant ascites in patients with terminal cancer is effectively treated with permanent peritoneal catheter
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4548747/
https://www.ncbi.nlm.nih.gov/pubmed/26346641
http://dx.doi.org/10.1177/2058460115579934
work_keys_str_mv AT meiermichelle malignantascitesinpatientswithterminalcanceriseffectivelytreatedwithpermanentperitonealcatheter
AT mortensenfrankv malignantascitesinpatientswithterminalcanceriseffectivelytreatedwithpermanentperitonealcatheter
AT madsenhanshenriktorp malignantascitesinpatientswithterminalcanceriseffectivelytreatedwithpermanentperitonealcatheter